Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BBNX NASDAQ:INGN NASDAQ:SIBN NASDAQ:TNDM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBBNXBeta Bionics$19.02+1.0%$15.23$8.89▼$24.50$826.80MN/A526,822 shs461,799 shsINGNInogen$8.10+1.4%$7.06$5.70▼$12.91$219.02M1.78275,182 shs215,237 shsSIBNSiBone$16.45-1.3%$17.02$11.70▼$20.05$709.65M0.81425,178 shs255,221 shsTNDMTandem Diabetes Care$12.78+2.2%$14.62$9.98▼$47.60$863.53M1.451.74 million shs1.92 million shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBBNXBeta Bionics0.00%+7.97%+14.88%+4.90%+1,883,999,900.00%INGNInogen0.00%+3.63%+28.66%+25.04%-34.88%SIBNSiBone0.00%+3.86%-4.14%-11.80%+0.30%TNDMTandem Diabetes Care0.00%+3.30%-18.77%-39.36%-71.24%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBBNXBeta BionicsN/AN/AN/AN/AN/AN/AN/AN/AINGNInogen4.006 of 5 stars3.32.00.03.93.71.70.6SIBNSiBone4.0413 of 5 stars3.52.00.03.33.02.50.6TNDMTandem Diabetes Care4.6491 of 5 stars4.14.00.04.92.71.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBBNXBeta Bionics 2.75Moderate Buy$22.5618.59% UpsideINGNInogen 2.50Moderate Buy$11.0035.80% UpsideSIBNSiBone 3.00Buy$23.6743.87% UpsideTNDMTandem Diabetes Care 2.27Hold$22.4775.80% UpsideCurrent Analyst Ratings BreakdownLatest INGN, TNDM, BBNX, and SIBN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/21/2025TNDMTandem Diabetes CareCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$10.35 ➝ $11.008/11/2025SIBNSiBoneCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetOverweight ➝ Overweight$25.008/11/2025TNDMTandem Diabetes CareLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold$75.00 ➝ $12.008/8/2025TNDMTandem Diabetes CareBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$53.00 ➝ $51.008/7/2025TNDMTandem Diabetes CareCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$59.00 ➝ $24.008/7/2025TNDMTandem Diabetes CarePiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Neutral$30.00 ➝ $14.008/7/2025TNDMTandem Diabetes CareUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$20.00 ➝ $17.008/7/2025TNDMTandem Diabetes CareWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$20.00 ➝ $13.008/7/2025TNDMTandem Diabetes CareRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$45.00 ➝ $25.008/5/2025SIBNSiBoneCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$25.007/30/2025BBNXBeta BionicsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$18.00 ➝ $21.00(Data available from 9/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBBNXBeta Bionics$65.12M12.70N/AN/A($5.72) per share-3.33INGNInogen$335.70M0.65N/AN/A$7.30 per share1.11SIBNSiBone$167.18M4.24N/AN/A$3.98 per share4.13TNDMTandem Diabetes Care$1.00B0.86N/AN/A$4.01 per share3.19Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBBNXBeta Bionics-$54.76MN/A0.00∞N/AN/AN/AN/AN/AINGNInogen-$35.89M-$1.06N/AN/AN/A-7.58%-13.77%-8.52%11/6/2025 (Estimated)SIBNSiBone-$30.91M-$0.56N/AN/AN/A-12.83%-14.20%-10.38%11/11/2025 (Estimated)TNDMTandem Diabetes Care-$96.03M-$3.09N/AN/AN/A-20.51%-65.40%-13.87%11/5/2025 (Estimated)Latest INGN, TNDM, BBNX, and SIBN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025INGNInogen-$0.22-$0.15+$0.07-$0.15$90.40 million$92.28 million8/6/2025Q2 2025TNDMTandem Diabetes Care-$0.40-$0.48-$0.08-$0.78$238.39 million$240.68 million8/4/2025Q2 2025SIBNSiBone-$0.19-$0.14+$0.05-$0.14$48.12 million$48.63 million7/29/2025Q2 2025BBNXBeta Bionics-$0.51-$0.39+$0.12-$0.39$19.73 million$23.24 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBBNXBeta BionicsN/AN/AN/AN/AN/AINGNInogenN/AN/AN/AN/AN/ASIBNSiBoneN/AN/AN/AN/AN/ATNDMTandem Diabetes CareN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBBNXBeta BionicsN/A14.6813.79INGNInogenN/A3.032.67SIBNSiBone0.218.387.00TNDMTandem Diabetes Care2.322.441.88Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBBNXBeta BionicsN/AINGNInogen89.94%SIBNSiBone98.11%TNDMTandem Diabetes CareN/AInsider OwnershipCompanyInsider OwnershipBBNXBeta BionicsN/AINGNInogen1.46%SIBNSiBone3.90%TNDMTandem Diabetes Care1.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBBNXBeta Bionics29443.47 millionN/AN/AINGNInogen1,03027.04 million26.65 millionOptionableSIBNSiBone35043.14 million41.46 millionOptionableTNDMTandem Diabetes Care2,65067.57 million66.29 millionOptionableINGN, TNDM, BBNX, and SIBN HeadlinesRecent News About These CompaniesDAFNA Capital Management LLC Buys 71,000 Shares of Tandem Diabetes Care, Inc. $TNDMSeptember 1 at 7:14 AM | marketbeat.comKingdon Capital Management L.L.C. Lowers Holdings in Tandem Diabetes Care, Inc. $TNDMSeptember 1 at 6:11 AM | marketbeat.comCapital Fund Management S.A. Trims Stock Holdings in Tandem Diabetes Care, Inc. $TNDMAugust 29, 2025 | marketbeat.comTandem Diabetes Care, Inc. $TNDM Shares Acquired by HighTower Advisors LLCAugust 28, 2025 | marketbeat.comNuveen LLC Invests $5.91 Million in Tandem Diabetes Care, Inc. $TNDMAugust 28, 2025 | marketbeat.comRussell Investments Group Ltd. Has $2.67 Million Stake in Tandem Diabetes Care, Inc. $TNDMAugust 27, 2025 | marketbeat.comCharles Schwab Investment Management Inc. Sells 32,171 Shares of Tandem Diabetes Care, Inc. $TNDMAugust 26, 2025 | marketbeat.comTandem Diabetes Care (NASDAQ:TNDM) Stock Price Up 7.4% Following Analyst UpgradeAugust 24, 2025 | americanbankingnews.comTandem Diabetes Care Inc News (TNDM) - Investing.comAugust 23, 2025 | investing.comTandem Diabetes Care, Inc. $TNDM Shares Purchased by Aberdeen Group plcAugust 23, 2025 | marketbeat.comVanguard Group Inc. Reduces Holdings in Tandem Diabetes Care, Inc. $TNDMAugust 23, 2025 | marketbeat.comTandem Diabetes Care (TNDM) Gets a Buy from RBC CapitalAugust 22, 2025 | theglobeandmail.comVersor Investments LP Buys Shares of 30,500 Tandem Diabetes Care, Inc. $TNDMAugust 22, 2025 | marketbeat.comAlgert Global LLC Purchases 119,784 Shares of Tandem Diabetes Care, Inc. $TNDMAugust 22, 2025 | marketbeat.comCitigroup Boosts Tandem Diabetes Care (NASDAQ:TNDM) Price Target to $11.00August 22, 2025 | americanbankingnews.comPublic Sector Pension Investment Board Raises Stock Position in Tandem Diabetes Care, Inc. $TNDMAugust 19, 2025 | marketbeat.comSector Gamma AS Acquires New Shares in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)August 17, 2025 | marketbeat.comTandem Diabetes Care, Inc. (NASDAQ:TNDM) Given Consensus Rating of "Hold" by BrokeragesAugust 15, 2025 | marketbeat.comTandem Diabetes Care, Inc. (TNDM) Investors Who Lost Money - Contact Law Offices of Howard G. Smith About Securities Fraud InvestigationAugust 14, 2025 | tmcnet.comSecurities Fraud Investigation Into Tandem Diabetes Care, Inc. ...August 14, 2025 | gurufocus.comSecurities Fraud Investigation Into Tandem Diabetes Care, Inc. (TNDM) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law FirmAugust 14, 2025 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeINGN, TNDM, BBNX, and SIBN Company DescriptionsBeta Bionics NASDAQ:BBNX$19.02 +0.18 (+0.96%) As of 04:00 PM EasternBeta Bionics, Inc. is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.Inogen NASDAQ:INGN$8.10 +0.11 (+1.38%) Closing price 04:00 PM EasternExtended Trading$8.10 0.00 (-0.06%) As of 04:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Inogen, Inc., a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company offers Inogen One, a portable device that concentrate the air around the patient to provide a source of supplemental oxygen; Inogen At Home stationary oxygen concentrators; Simeox airway clearance; batteries; and related accessories. It also rents its products directly to patients. Inogen, Inc. was incorporated in 2001 and is headquartered in Goleta, California.SiBone NASDAQ:SIBN$16.45 -0.22 (-1.32%) Closing price 04:00 PM EasternExtended Trading$16.45 0.00 (0.00%) As of 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.SI-BONE, Inc., a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; iFuse-TORQ, a set of 3D-printed threaded implants designed to treat pelvic trauma; and iFuse Bedrock Granite implant provides sacroiliac fusion and sacropelvic fixation as a foundational element for segmental spinal fusion. It markets its products primarily with a direct sales force, as well as through agents and resellers. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.Tandem Diabetes Care NASDAQ:TNDM$12.78 +0.27 (+2.16%) Closing price 04:00 PM EasternExtended Trading$12.56 -0.23 (-1.76%) As of 05:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Loop Industries Insiders Buy Stock, Signal Confidence in Outlook Joby Aviation's Pullback: A Gift for Investors Who See the Future Kohl’s Stock Rebound Faces a Showdown With Short Sellers What to Watch for From D-Wave Now That Earnings Are Done 3 High-Yield Stocks Just Supercharged Their Dividends MarketBeat Week in Review – 08/25 - 08/29 Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Alphabet’s Resurgence: It's Now a Clear Market Leader Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
